PTAFR and Carcinoma, Lewis Lung: We have also shown that the systemic administration of a known PAFR-agonist, carbamoyl-PAF (CPAF) can augment the growth of Lewis lung carcinoma (LLC1) tumors and its metastatic ability in a PAFR-dependent manner [33].